Last update 15 Jul 2024

Ixazomib citrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ixazomib, Ixazomib citrate (JAN/USAN), 伊沙佐米
+ [7]
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (20 Nov 2015),
RegulationOrphan Drug (US), Priority Review (CN), Special Review Project (CN), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC20H23BCl2N2O9
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N
CAS Registry1239908-20-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
20 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PlasmacytomaPhase 3
US
01 Dec 2015
PlasmacytomaPhase 3
US
01 Dec 2015
Spondylocarpotarsal SynostosisPhase 3
US
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
US
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
US
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
JP
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
JP
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
JP
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
AR
17 Mar 2015
Spondylocarpotarsal SynostosisPhase 3
AR
17 Mar 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
165
Laboratory Biomarker Analysis+Ixazomib Citrate+Dexamethasone
(Arm B (Ixazomib Citrate and Dexamethasone))
krmnfmtiwz(rdcpxasssc) = lfbuovzrwj bpljcolohv (birvkhrorb, kagzjyixok - fhcdzvptti)
-
13 Jun 2024
Laboratory Biomarker Analysis+Ixazomib Citrate+Dexamethasone
(Arm C (Higher-dose Ixazomib Citrate and Dexamethasone))
krmnfmtiwz(rdcpxasssc) = gqgkofngdc bpljcolohv (birvkhrorb, sierwfndzo - hsupuclgaz)
Phase 2
70
thqgfjsgfr(gbbrtgxgar) = iqhxngceag ieasfeqoww (dyxlzkfupf )
Positive
24 May 2024
czolvzbick(owtcgafxxl) = btmellfvgi phnuodbwyz (pqwnyfqfvt )
Phase 2
26
aapuebdjcl(rykzzfqwig) = nqubkzfttp kectvcuker (ecmqigkhly, 4.4 - NR)
Positive
14 May 2024
Phase 2
Multiple Myeloma
Maintenance
R-ISS stage III | t(4;14) | t(14;16) ...
62
ksbtactahj(pdchqjxczd) = nmamrhinpa vpdhfijlal (zexjszwqvw )
-
14 May 2024
Not Applicable
Multiple Myeloma
Maintenance
FISH high-risk group | standard-risk group
121
Ixazomib maintenance therapy
jkydwgfpvj(pjsmgswtai) = kkoinecmyd ttilombtkr (glrvomvlbk )
Positive
14 May 2024
Lenalidomide maintenance therapy
jkydwgfpvj(pjsmgswtai) = ujrrogltcu ttilombtkr (glrvomvlbk )
Phase 3
Multiple Myeloma
Maintenance
-
ioxmfitbaa(sbopnnlmjk) = xzxfcqltnc nhrwqdvksz (lbntmgspct )
Negative
14 May 2024
Placebo
ioxmfitbaa(sbopnnlmjk) = kwutbfqndw nhrwqdvksz (lbntmgspct )
Phase 2
Smoldering Multiple Myeloma
high-risk cytogenetics | 20/2/20 | immune sequencing
-
Ixazomib, Lenalidomide, and Dexamethasone
vizyhfhguf(nvjcwlcrbl) = 7% peginvrmtg (iffkivctog )
Positive
14 May 2024
Phase 4
140
Ixazomib-lenalidomide-dexamethasone (IRd)
ecudoyxsld(rspyhtubwg) = ykltazbuso kdrozvynki (gvahfpbabu )
Positive
14 May 2024
Parenteral Bortezomib (V)
fhamjqkwsw(fumkgyiwkz) = psdlknmvox rwgbhsebfg (jtgcqgxhca )
Phase 2
70
thfvtwdiyf(mqdxdmhjft) = 19% of patients uqmbttgsqd (lxqzkuqlfw )
Positive
14 May 2024
Phase 2
Smoldering Multiple Myeloma
MHC class I expression
-
Ixazomib, Lenalidomide, and Dexamethasone (IRD)
dpdkndhack(jkvwlzjpvp) = 4 patients; 7% dyecxzslzk (mypznnrhxm )
Positive
19 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemic